Skip Navigation

Matthew H. Kulke, MD


Medical Oncology

Make an Appointment

Physician

  • Director, Program in Neuroendocrine and Carcinoid Tumors
  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gastrointestinal cancers
  • Neuroendocrine tumors

Diseases Treated

  • Neuroendocrine Tumors

Contact Information

  • Appointments617.632.5929
  • Office Phone Number617-632-5136
  • Fax617-632-5370

Bio

Matthew Kulke joined the staff of Dana-Farber Cancer Institute in 1997 and is currently a Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. 

He received an M.D. from the University of California, San Francisco School of Medicine in 1992. He subsequently completed an internship and residency in internal medicine at Brigham and Women's Hospital, a fellowship in medical oncology at Dana-Farber, and received a masters degree in medical science from Harvard Medical School.

Dr. Kulke has led numerous clinical and translational studies in patients with gastrointestinal malignancies and neuroendocrine tumors. He has served as study chair for a national study of pancreatic cancer therapies performed by the Cancer and Leukemia group B and funded by the National Cancer Institute.

His current efforts have focused on clinical and translational research in carcinoid and pancreatic neuroendocrine tumors.

Dr. Kulke is the recipient of the George Canellos Award for Clinical Investigation and the Ruth Brufsky Award for Pancreatic Cancer Research. He serves on the advisory board for the European Neuroendocrine Tumor Society, the executive committee of the North American Neuroendocrine Tumor Society, and is chair of the Neuroendocrine Tumor Task force for the National Cancer Institute.

Board Certification:

  • Internal Medicine, 2005
  • Medical Oncology, 1999

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • University of California, San Francisco School of Medicine

Recent Awards:

  • Young Investigator Award, American Society of Clinical Oncology 1998-1999
  • Discovery Fellowship, Dana-Farber Cancer Institute 1999-2001
  • George Canellos Award for Contributions to Clinical Research, Dana-Farber Cancer Institute 2003
  • Ruth Brufsky Award for Excellence in Clinical Research on Pancreatic Cancer, University of Pittsburgh School of Medicine 2009

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1220
Boston MA, 02215
Get Directions

Research

Gastrointestinal Malignancies and Neuroendocrine Tumors

We have established a robust clinical and translational research program at Dana-Farber Cancer Institute, focused on neuroendocrine tumors. As part of our clinical research program, we evaluate over 200 neuroendocrine tumor patients annually and have studied numerous novel therapies for neuroendocrine tumor patients.

Our research has included early studies demonstrating activity of the small molecule tyrosine kinase inhibitor sunitinib and the oral alkylating agent temozolomide in patients with neuroendocrine tumors. We are currently evaluating novel combinations of therapeutic agents in neuroendocrine tumors, including regimens of temozolomide/everolimus and pasireotide/everolimus.

The temozolomide/everolimus combination will be further evaluated and compared to bevacizumab/everolimus or everolimus alone in a planned cooperative group trial, under the auspices of the Cancer and Leukemia Group B.

The foundation of our translational research efforts in neuroendocrine tumors is a database of clinical information and biospecimens collected prospectively from over 900 neuroendocrine tumor patients, beginning in 2003. We have used this resource to identify predictive and prognostic factors in patients undergoing treatment for neuroendocrine tumors.

In recent studies, we have identified alkaline phosphatase as a prognostic marker in patients with advanced neuroendocrine tumors. We have also been able to utilize our biospecimen collection to demonstrate loss of the DNA repair enzyme MGMT in pancreatic neuroendocrine tumors, and to correlate MGMT loss with response to temozolomide-based regimens.

The rapid development of genomic technology has created several new opportunities to better understand the genetic underpinnings of neuroendocrine tumors. Using single nucleotide polymorphism arrays, we confirmed loss of chromosome 18 as a common event in small bowel carcinoid tumors, and identified recurrent amplifications on chromosome 14 in the vicinity of the anti-apoptosis gene DAD1.

We are now performing studies evaluating the effect of genetic variation in DAD1 and other candidate genes on neuroendocrine tumor risk and outcome.

Shi Y, Qian ZR, Zhang S, Li W, Masugi Y, Li T, Chan JA, Yang J, Da Silva A, Gu M, Liu L, Hamada T, Kosumi K, Dutton T, Brais LK, Nishihara R, Fuchs CS, Ogino S, Kulke MH. Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index. Pancreas. 2017 Nov/Dec; 46(10):1347-1353.
View in: PubMed

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-Controlled Study of Telotristat Ethyl. Clin Ther. 2017 Oct 23.
View in: PubMed

Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2017 Oct 21.
View in: PubMed

Hope TA, Bergsland E, Bozkurt MF, Graham MM, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2017 Oct 12.
View in: PubMed

Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct; 18(10):1411-1422.
View in: PubMed

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017 Jun 01; 28(6):1309-1315.
View in: PubMed

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2017 May 24.
View in: PubMed

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
View in: PubMed

Kulke MH. Novel Treatment Options for Neuroendocrine Tumors. J Natl Compr Canc Netw. 2017 May; 15(5S):737-739.
View in: PubMed

Bowden M, Zhou CW, Zhang S, Brais L, Rossi A, Naudin L, Thiagalingam A, Sicinska E, Kulke MH. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget. 2017 Aug 15; 8(33):54331-54344.
View in: PubMed

Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May 20; 35(15):1695-1703.
View in: PubMed

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology. 2017; 105(3):281-294.
View in: PubMed

Kulke MH. Advances in the management of patients with carcinoid syndrome. Clin Adv Hematol Oncol. 2017 Apr; 15(4):257-259.
View in: PubMed

Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017; 105(3):266-280.
View in: PubMed

Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol. 2017 Aug; 24(8):2319-2325.
View in: PubMed

Shi DD, Yuppa DP, Dutton T, Brais LK, Minden SL, Braun IM, Kulke MH, Chan JA, Meyer FL. Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. Cancer. 2017 Jul 15; 123(14):2735-2742.
View in: PubMed

Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017; 105(3):196-200.
View in: PubMed

Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist. 2017 Feb; 22(2):165-172.
View in: PubMed

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
View in: PubMed

Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, Liu G. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiol. 2017 Apr; 47:28-34.
View in: PubMed

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
View in: PubMed

Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, Oukrif D, Mandair D, Pericleous M, Mohmaduvesh M, Serra S, Ogunbiyi O, Novelli M, Luong T, Asa SL, Kulke M, Toumpanakis C, Meyer T, Caplin M, Beck S, Thirlwell C. Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocr Relat Cancer. 2017 Feb; 24(2):L21-L25.
View in: PubMed

Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov; 45(10):1386-1393.
View in: PubMed

Yao J, Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Pacaud L, Ridolfi A, Singh S, Pavel M, Kulke M. ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S253.
View in: PubMed

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23.
View in: PubMed

Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget. 2016 Oct 11; 7(41):66328-66343.
View in: PubMed

Kulke MH. Emerging treatment options for carcinoid syndrome. Clin Adv Hematol Oncol. 2016 Sep; 14(9):666-7.
View in: PubMed

Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016 Sep; 5(5):174-87.
View in: PubMed

Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P, Christiani DC, Kulke MH. Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer. 2016 Aug; 23(8):587-94.
View in: PubMed

Song C, Liu Y, Fontana R, Makrigiorgos A, Mamon H, Kulke MH, Makrigiorgos GM. Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. Nucleic Acids Res. 2016 Nov 02; 44(19):e146.
View in: PubMed

Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 Jul 13; 16:468.
View in: PubMed

Gelhorn HL, Kulke MH, O'Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P, Lapuerta P. Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. Clin Ther. 2016 04; 38(4):759-68.
View in: PubMed

Kulke MH. Somatostatin Analogues in Neuroendocrine Tumors. J Natl Compr Canc Netw. 2016 Mar; 14(3):241-2.
View in: PubMed

Chan JA, Kulke MH. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. Surg Oncol Clin N Am. 2016 Apr; 25(2):423-37.
View in: PubMed

Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res. 2016 Feb; 36(2):713-9.
View in: PubMed

Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016 Jan; 53:163-70.
View in: PubMed

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977.
View in: PubMed

Chan JA, Kulke MH. Neuroendocrine Tumors--Current and Future Clinical Advances. Hematol Oncol Clin North Am. 2016 Feb; 30(1):xiii-xiv.
View in: PubMed

Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, Oukrif D, Mandair D, Pericleous M, Mohmaduvesh M, Serra S, Ogunbiyi O, Novelli M, Luong T, Asa SL, Kulke M, Toumpanakis C, Meyer T, Caplin M, Meyerson M, Beck S, Thirlwell C. Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clin Cancer Res. 2016 Jan 01; 22(1):250-8.
View in: PubMed

Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
View in: PubMed

Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Fazio N. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2015; 101(4):274-88.
View in: PubMed

Kulke MH. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors. J Clin Oncol. 2015 May 10; 33(14):1534-8.
View in: PubMed

Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer. 2015 Mar 31; 112(7):1199-205.
View in: PubMed

Cohen JM, Nambudiri VE, Kulke MH, Todd DJ, Murphy GF, LeBoeuf NR. Cutaneous paraneoplastic granulomatous eruptions secondary to metastatic carcinoid tumour. Br J Dermatol. 2015; 172(5):1451-4.
View in: PubMed

Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108.
View in: PubMed

Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS, Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BM. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
View in: PubMed

Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015; 66:1-16.
View in: PubMed

Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014 Sep; 15(3):365-79.
View in: PubMed

Kulke M. Neuroendocrine tumors: answers-and questions. Oncology (Williston Park). 2014 Sep; 28(9):758, 760.
View in: PubMed

Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov; 86(2):241-6.
View in: PubMed

Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014 Oct 28; 111(9):1772-9.
View in: PubMed

Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014 Sep; 19(9):930-6.
View in: PubMed

Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014 Sep; 46(9):994-1000.
View in: PubMed

Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
View in: PubMed

Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec; 45(12):1483-6.
View in: PubMed

Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. Cancer Res. 2013 Dec 01; 73(23):6865-73.
View in: PubMed

Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, Li S, Christiani DC, Liu G. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. J Gastroenterol Hepatol. 2013 Sep; 28(9):1482-8.
View in: PubMed

Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol. 2013 Sep 20; 31(27):3418-25.
View in: PubMed

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013 Sep 01; 119(17):3212-8.
View in: PubMed

Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013 Jun; 20(3):383-90.
View in: PubMed

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May; 42(4):557-77.
View in: PubMed

Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32.
View in: PubMed

Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013 Apr; 20(2):187-96.
View in: PubMed

Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2013 May; 71(5):1241-6.
View in: PubMed

Oberg K, Casanovas O, Castaño JP, Chung D, Delle Fave G, Denèfle P, Harris P, Khan MS, Kulke MH, Scarpa A, Tang LH, Wiedenmann B. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013 Jun 01; 19(11):2842-9.
View in: PubMed

Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):75-83.
View in: PubMed

Yao J, Reidy Lagunes D, Kulke MH. In reply. Oncologist. 2013; 18(11):1240-1.
View in: PubMed

Kulke MH. Are neuroendocrine tumors going mainstream? J Clin Oncol. 2013 Feb 01; 31(4):404-5.
View in: PubMed

Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012 Oct; 19(5):615-23.
View in: PubMed

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8.
View in: PubMed

Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11306-11.
View in: PubMed

Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
View in: PubMed

Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):724-64.
View in: PubMed

Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012 May 07; 12:153-62.
View in: PubMed

Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, Liu G. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012 Dec 01; 131(11):2478-86.
View in: PubMed

Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2012 Mar; 41(1):119-31.
View in: PubMed

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
View in: PubMed

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist. 2012; 17(1):14-e35.
View in: PubMed

Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
View in: PubMed

Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb 01; 118(3):804-11.
View in: PubMed

Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011 Jun 14; 4:29.
View in: PubMed

Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol. 2011 Jun; 12(2):136-48.
View in: PubMed

Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis. 2011 Aug; 32(8):1216-22.
View in: PubMed

Kulke M, O'Dorisio TM, Phan AT, Langdon RM, Marek BJ, Iklaque N, Bergsland EK, Freiman J, Frazier K, Jackson J, Zambrowicz B. A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS168.
View in: PubMed

Chan JA, Ryan DP, Fuchs CS, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan E, Kulke M. Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). J Clin Oncol. 2011 May 20; 29(15_suppl):4120.
View in: PubMed

Zurita AJ, Heymach J, Khajavi M, Tye L, Huang X, Kulke M, Lenz H, Meropol NJ, Carley W, DePrimo SE, Harmon CS. Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):4079.
View in: PubMed

Renouf DJ, Sun B, Zhai R, Xu W, Heist RS, Kulke M, Su L, Christiani DC, Liu G. Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease (GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC). J Clin Oncol. 2011 May 20; 29(15_suppl):10595.
View in: PubMed

Coate LE, Zhai R, Xu W, Chen Z, Asomaning K, Kulke M, Heist RS, Christiani D, Liu G. Early adulthood obesity, cumulative smoking, and esophageal cancer survival. J Clin Oncol. 2011 May 20; 29(15_suppl):1546.
View in: PubMed

Wo JY, Ryan DP, Kulke MH, Hong TS. Radiation recall associated with insulin growth factor 1R antibody. Pract Radiat Oncol. 2011 Jul-Sep; 1(3):208-11.
View in: PubMed

Wu IC, Zhao Y, Zhai R, Liu G, Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, Heist RS, Christiani DC. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia. 2011 Apr; 13(4):386-92.
View in: PubMed

Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2011 Jun; 34(3):566-72.
View in: PubMed

Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist. 2011; 16(3):286-95.
View in: PubMed

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
View in: PubMed

Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011 Feb; 18(1):171-80.
View in: PubMed

Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, Asomaning K, Su L, Heist RS, Kulke MH, Liu G, Christiani DC. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis. 2011 Apr; 32(4):502-6.
View in: PubMed

Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol. 2011 Aug; 68(2):293-300.
View in: PubMed

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug; 39(6):799-800.
View in: PubMed

Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug; 39(6):735-52.
View in: PubMed

Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, Liu G, Christiani DC. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010 Jul; 31(7):1259-63.
View in: PubMed

Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, Sevilla Garcia I, Scoazec JY, Nilsson O, Fazio N, Lesurtel M, Chen YJ, Eriksson B, Cioppi F, O'Toole D. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010; 91(4):333-40.
View in: PubMed

Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010 May 10; 28(14):2445-51.
View in: PubMed

Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010 Mar; 34(3):300-13.
View in: PubMed

Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2010 Oct; 66(5):961-8.
View in: PubMed

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 01; 28(1):69-76.
View in: PubMed

Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
View in: PubMed

Kulke MH, Scherübl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S62-6.
View in: PubMed

Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009 Aug; 19(8):613-25.
View in: PubMed

Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 04; 101(3):465-72.
View in: PubMed

Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47.
View in: PubMed

Cheung WY, Zhai R, Kulke MH, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, Liu G. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009 Aug; 30(8):1363-7.
View in: PubMed

Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, Wang Z, Su L, Christiani D, Liu G. Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. J Clin Oncol. 2009 May 20; 27(15_suppl):11029.
View in: PubMed

Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep. 2009 May; 11(3):193-9.
View in: PubMed

Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ, Christiani DC, Liu G. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res. 2009 May 01; 15(9):3103-9.
View in: PubMed

Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009 May; 30(5):793-8.
View in: PubMed

Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 2010 Jan; 23(1):36-9.
View in: PubMed

Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
View in: PubMed

Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7.
View in: PubMed

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45.
View in: PubMed

Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, Nishioka NS, Lynch TJ, Wain JC, Lin X, Christiani DC. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008 Dec; 29(12):2330-4.
View in: PubMed

Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
View in: PubMed

Mamon H, Hader C, Li J, Wang L, Kulke M, Amicarelli G, Shehi E, Adlerstein D, Roper K, Killion L, Hooshmand S, Makrigiorgos GM. Preferential amplification of apoptotic DNA from plasma: potential for enhancing detection of minor DNA alterations in circulating DNA. Clin Chem. 2008 Sep; 54(9):1582-4.
View in: PubMed

Sheehy N, Kulke MH, Van den Abbeele AD. F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
View in: PubMed

Fujiki K, Duerr EM, Kikuchi H, Ng A, Xavier RJ, Mizukami Y, Imamura T, Kulke MH, Chung DC. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology. 2008 Sep; 135(3):907-16, 916.e1-2.
View in: PubMed

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10.
View in: PubMed

Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer. 2008 Jul; 47(7):591-603.
View in: PubMed

Cescon DW, Bradbury PA, Asomaning K, Zhai R, Kulke M, Su L, Heist RS, Wain JC, Lynch TJ, Christiani DC, Liu G. p53 Arg72Pro, MDM2 T309G, CCND1 G870A polymorphisms, histology and esophageal cancer prognosis. J Clin Oncol. 2008 May 20; 26(15_suppl):11033.
View in: PubMed

Kulke MH. Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res. 2008 May; 2(3):152-3.
View in: PubMed

Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008 May; 14(5):579-84.
View in: PubMed

Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008 Mar; 15(1):243-56.
View in: PubMed

Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
View in: PubMed

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92.
View in: PubMed

Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008; 87(1):20-30.
View in: PubMed

Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007 Sep; 9(4):441-51.
View in: PubMed

Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008 Feb; 53(2):564-70.
View in: PubMed

Bradbury PA, Marshall AL, Kulke MH, Zhou W, Heist RS, Su L, Lynch TJ, Shepherd FA, Christiani DC, Liu G. Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A2511.
View in: PubMed

Bhargava P, Earle CC, Zhu AX, Clark JW, Vincitore M, Battu S, Regan E, Lawrence C, Kulke MH . A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs) . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A15149.
View in: PubMed

Kulke MH, Frauenhoffer CS, Hooshmand SM, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Hornick J, Fuchs C, Redston MS. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A4505.
View in: PubMed

Singh S, Asomaning K, Kulke MH, Zhou W, Zhai R, Su L, Heist RS, Lynch TJ, Christiani DC, Liu G . MMP1 1G/2G promoter polymorphism and risk of esophageal adenocarcinoma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A10555.
View in: PubMed

Blaszkowsky LS, Ryan DP, Earle C, Kwak E, Fuchs C, Meyerhardt JA, tuart K, Zhu AX, Enzinger P, Kulke MH. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A15080.
View in: PubMed

Mackay HJ, Bradbury P, Asomaning K, Zhou W, Kulke MH, Su L, Suk Heist R, Lynch TJ, Christiani DC, Liu G. Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS) . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A21047.
View in: PubMed

Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007 Jun; 21(3):433-55; vii-viii.
View in: PubMed

Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest. 2007 Jun; 25(4):249-55.
View in: PubMed

Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer. 2007 Jun; 14(2):207-19.
View in: PubMed

Kulke MH. New developments in the treatment of gastrointestinal neuroendocrine tumors. Curr Oncol Rep. 2007 May; 9(3):177-83.
View in: PubMed

Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs. 2007 May; 12(2):253-70.
View in: PubMed

Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
View in: PubMed

Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61.
View in: PubMed

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7.
View in: PubMed

Bello C, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum C, Meropol NJ, Lenz H, Kulke MH. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4045.
View in: PubMed

Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4044.
View in: PubMed

Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93.
View in: PubMed

Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 May; 51(5):877-84.
View in: PubMed

Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. . Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(No. 18s):A4044.
View in: PubMed

Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest. 2006 Jun-Jul; 24(4):346-50.
View in: PubMed

Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun; 51(6):1033-8.
View in: PubMed

Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006 Jun; 43(6):383-450.
View in: PubMed

Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7.
View in: PubMed

Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 2006 Apr-May; 24(3):229-34.
View in: PubMed

Li J, Wang F, Mamon H, Kulke MH, Harris L, Maher E, Wang L, Makrigiorgos GM. Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples. Clin Chem. 2006 Apr; 52(4):624-33.
View in: PubMed

Li J, Harris L, Mamon H, Kulke MH, Liu WH, Zhu P, Mike Makrigiorgos G. Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma. J Mol Diagn. 2006 Feb; 8(1):22-30.
View in: PubMed

McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol. 2006 Feb; 29(1):40-4.
View in: PubMed

Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38.
View in: PubMed

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20; 24(3):401-6.
View in: PubMed

Kulke MH, Sommers R, Morgan JA. Role of systemic chemotherapy in the treatment of advanced neuroendocrine tumors. Am J of Hem/Onc. 2006; 5:430-33.
View in: PubMed

Bello CL, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum CM, Meropol NJ, Lenz H, Kulke MH. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(18s):A4045.
View in: PubMed

Kulke M, Fuchs C. Cancer of the Appendix. Raghavan D, editor. Textbook of the Uncommon Cancer. 2006; 410-417.
View in: PubMed

Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23.
View in: PubMed

Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
View in: PubMed

Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
View in: PubMed

Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol. 2005 Sep; 6(5):397-409.
View in: PubMed

Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul; 10(6):392-8.
View in: PubMed

Kulke M, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol. 2005 Jun; 23(16_suppl):4008.
View in: PubMed

Clark JW, Zhu AX, Ryan DP, Meyerhardt J, Enzinger P, Earle C, Fuchs C, Anbe H, Houghton M, Kulke M. Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). J Clin Oncol. 2005 Jun; 23(16_suppl):4066.
View in: PubMed

Kulke MH. Combination chemotherapy for advanced pancreatic cancer--has its time finally come? Lancet Oncol. 2005 Jun; 6(6):352-3.
View in: PubMed

Blaszkowsky LS, Kulke MH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, Lawrence C, Fuchs CS. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I of II. 2005; 23(16S ):A4099.
View in: PubMed

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I of II. 2005; 23(No. 16S):A4008.
View in: PubMed

Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke MH, Ryan DP, Michelini A, Langford L, Meyerhardt J. Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol. 2005; A28.
View in: PubMed

McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8.
View in: PubMed

Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004 Oct 01; 95(7):708-16.
View in: PubMed

Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 01; 101(5):934-9.
View in: PubMed

McCollum AD, Wu B, Clark J, Kulke M, Enzinger P, Ryan D, Earle C, Michelini A, Fuchs C. Capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3657.
View in: PubMed

Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4040.
View in: PubMed

Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4011.
View in: PubMed

Meyerhardt JA, Xhu A, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Michelini A, Vincitore M, Thomas A, Fuchs CS. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3580.
View in: PubMed

Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004 Jun; 127(6):1579-86.
View in: PubMed

Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke MH, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(No. 14S):A4040.
View in: PubMed

Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(14S):A4011.
View in: PubMed

Kulke M, Mayer R. Management Options: Metastatic Gastric Carcinoma. Abruzzese J, editor. Gastrointestinal Oncology. 2004; 316-325.
View in: PubMed

Kulke M, Fuchs C. Clinical Aspects and Management of Small Bowel and Appendiceal Cancers: Management Options - Unresectable, Locally Advanced and Metastatic Small Bowel and Appendiceal Carcinomas. Abruzzese J, editor. Gastrointestinal Oncology. 2004; 585-590.
View in: PubMed

Kulke M. Ablative Therapies in Gastrointestinal Malignancies. Van Sonnenberg E and McMullin W, editors. Tumor Ablation: Principles and Practice. 2004; 466-471.
View in: PubMed

Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22(3):353-9.
View in: PubMed

Kulke MH. Advanced pancreatic cancer: is there a role for combination therapy? Expert Rev Anticancer Ther. 2003 Oct; 3(5):729-39.
View in: PubMed

Kulke MH. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat Rev. 2003 Oct; 29(5):363-70.
View in: PubMed

Kulke MH. Recent developments in the pharmacological treatment of advanced pancreatic cancer. Expert Opin Investig Drugs. 2003 Jun; 12(6):983-92.
View in: PubMed

Levine RL, George DJ, Kulke MH. Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. Clin Adv Hematol Oncol. 2003 Feb; 1(2):99-100; discussion 100.
View in: PubMed

Kulke M. Neuroendocrine Tumors. Furie B, Mayer RJ, Cassileth PA, Atkins MB, editors. Clinical Practice of Hematology and Oncology. 2003; 1113-1138.
View in: PubMed

Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11.
View in: PubMed

Kulke MH. Metastatic pancreatic cancer. Curr Treat Options Oncol. 2002 Dec; 3(6):449-57.
View in: PubMed

Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9.
View in: PubMed

Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002 Jun 15; 94(12):3186-91.
View in: PubMed

Kulke M. Cancer of the Gastrointestinal Tract. Skarin AT, editor. Atlas of Diagnostic Oncology. 2002; 111-160.
View in: PubMed

Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 01; 94(1):97-103.
View in: PubMed

Kulke M. Book Review: Gastrointestinal Oncology: Principles and Practice. N Engl J Med. 2002; 347:1124.
View in: PubMed

Ellis FH, Xu X, Kulke MH, LoCicero J, Loda M. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg. 2001 Oct; 122(4):809-14.
View in: PubMed

Kulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer. 2001 Apr 15; 91(8):1451-7.
View in: PubMed

Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer. 2001 Mar 23; 84(6):748-53.
View in: PubMed

Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD. Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1):121-6.
View in: PubMed

Kulke MH. The treatment of advanced gastric cancer: in search of the right combination. J Clin Oncol. 2000 Jul; 18(14):2645-7.
View in: PubMed

Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999 Mar 18; 340(11):858-68.
View in: PubMed

Kulke M, Osteen R, Fuchs C. Cancer of the Appendix. Raghavan D, editor. Textbook of Uncommon Cancer. 1999; 447-455.
View in: PubMed

Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis. 1997 Aug; 25(2):215-8.
View in: PubMed

Matthew H Kulke. Isolation of the partial genomic sequence of RHK7 (KV1.7), a novel Shaker-like voltage gated potassium channel. 1992.
View in: PubMed

Krueger J, Kulke M, Schutt C, Stock J. Protein inclusion body formation and purification. Biopharm. 1989; 40-45.
View in: PubMed

Matthew H Kulke. Characterization of three point mutants of the CheB methylesterase and a study of their precipitation into inclusion bodies. 1987.
View in: PubMed

Top